Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 3
Submit an article Journal homepage
521
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma

Jonathan M. LoreeDivision of Medical Oncology, BC Cancer Agency, Vancouver, Canada;
,
Ellen CaiDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada;
,
Brandon S. SheffieldDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada;
,
Jan P. DutzDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada;
,
Diego VillaDivision of Medical Oncology, BC Cancer Agency, Vancouver, Canada;
,
Lois E. ShepherdDepartment of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
,
Joseph M. ConnorsDivision of Medical Oncology, BC Cancer Agency, Vancouver, Canada;
,
Laurie H. SehnDivision of Medical Oncology, BC Cancer Agency, Vancouver, Canada;
&
Kerry J. SavageDivision of Medical Oncology, BC Cancer Agency, Vancouver, Canada; Correspondence[email protected]
 show all
Pages 711-714 | Received 25 May 2016, Accepted 16 Jun 2016, Published online: 25 Aug 2016

References

  • Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15:730–737.
  • Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 201'4;165:375–381.
  • Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
  • Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
  • Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13:424–429.
  • Fowler NH, Nastoupil LJ, Hagemeister FB, et al. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 2015;100:e454–e457.
  • Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635–3640.
  • Breccia M, Cannella L, Latagliata R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. J Clin Oncol. 2011;29:402–403.
  • Yildirim ND, Ayer M, Küçükkaya RD, et al. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. Jpn J Clin Oncol. 2007;37:704–707.
  • Witzens M, Moehler T, Neben K, et al. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Ann Hematol. 2004;83:467–470.
  • Montefusco V, Galli M, Spina F, et al. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma. 2014;55:2032–2037.
  • Goeser MR, Laniosz V, Wetter DA. Therapy in practice a practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. Am J Clin Dermatol. 2014;15:299–306.
  • Davis MDP, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2014;89:1515–1524.
  • Ramos-Casals M, Brito-Zerón P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22:847–861.
  • LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103:1787–1790.
  • Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161–169.
  • Postow MA, Callahan MK, Wolchok JD, et al. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.